PMID- 32865687
OWN - NLM
STAT- MEDLINE
DCOM- 20211101
LR  - 20211204
IS  - 1776-260X (Electronic)
IS  - 1776-2596 (Linking)
VI  - 15
IP  - 5
DP  - 2020 Oct
TI  - Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell 
      Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and 
      Meta-Analysis.
PG  - 589-598
LID - 10.1007/s11523-020-00745-7 [doi]
AB  - BACKGROUND: Crizotinib has been approved for the treatment of non-small-cell lung 
      cancer (NSCLC) with ROS proto-oncogene 1 (ROS1) gene fusion. This drug has also 
      been granted breakthrough designation for NSCLCs with MET exon 14 alterations. 
      OBJECTIVE: This systematic review and meta-analysis aimed to investigate the 
      efficacy and safety of crizotinib in patients with these diseases. METHODS: We 
      searched PubMed and Web of Science for relevant studies. Meta-analysis of 
      proportions was conducted to calculate the pooled rate of complete response, 
      partial response, stable disease, progressive disease, disease control rate 
      (DCR), objective response rate (ORR), and drug adverse effects (AEs) of 
      crizotinib in NSCLCs with ROS1 rearrangement or MET alterations. RESULTS: A total 
      of 20 studies were included for meta-analysis. Among patients with ROS1-positive 
      NSCLC, crizotinib exhibited a pooled DCR of 93.2% (95% confidence interval [CI] 
      90.8-95.5) and a pooled ORR of 77.4% (95% CI 72.8-82.1). The median 
      progression-free survival (PFS) and overall survival (OS) of patients in this 
      group was 14.5 and 32.6 months, respectively. For NSCLC with MET alterations, 
      crizotinib was associated with a lower efficacy (DCR 78.9% [95% CI 70.3-87.4] and 
      ORR 40.6% [95% CI 28.3-53.0]). The median PFS was 5.2 months, and median OS was 
      12.7 months. The most common drug AEs were vision impairment (43.7%), edema 
      (42.9%), and fatigue (40.1%). CONCLUSION: Our study highlighted and confirmed the 
      efficacy of crizotinib in patients with NSCLC with ROS1 or MET genetic 
      alterations. Crizotinib had remarkable effects on advanced NSCLC with ROS1 
      fusion, as previously reported. However, the role of this targeted therapy in 
      MET-altered NSCLC remains investigational.
FAU - Vuong, Huy Gia
AU  - Vuong HG
AUID- ORCID: 0000-0001-6213-765X
AD  - Department of Pathology, Oklahoma University Health Sciences Center, Oklahoma 
      City, OK, 73104, USA. huyvuong@hotmail.com.
AD  - Stephenson Cancer Center, Oklahoma University of Health Sciences Center, Oklahoma 
      City, OK, 73104, USA. huyvuong@hotmail.com.
FAU - Nguyen, Thu Quynh
AU  - Nguyen TQ
AD  - Faculty of Medicine, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, 
      700-000, Vietnam.
FAU - Nguyen, Hoang Cong
AU  - Nguyen HC
AD  - Faculty of Medicine, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, 
      700-000, Vietnam.
FAU - Nguyen, Phuoc Truong
AU  - Nguyen PT
AD  - Faculty of Medicine, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, 
      700-000, Vietnam.
FAU - Ho, An Thi Nhat
AU  - Ho ATN
AD  - Department of Pulmonary and Critical Care Medicine, Saint Louis University, St. 
      Louis, MO, 63104, USA.
FAU - Hassell, Lewis
AU  - Hassell L
AD  - Department of Pathology, Oklahoma University Health Sciences Center, Oklahoma 
      City, OK, 73104, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - France
TA  - Target Oncol
JT  - Targeted oncology
JID - 101270595
RN  - 0 (MAS1 protein, human)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Proto-Oncogene Mas)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 53AH36668S (Crizotinib)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (ROS1 protein, human)
SB  - IM
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Crizotinib/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Protein Kinase Inhibitors/pharmacology/*therapeutic use
MH  - Protein-Tyrosine Kinases/*metabolism
MH  - Proto-Oncogene Mas
MH  - Proto-Oncogene Proteins/*genetics/metabolism
EDAT- 2020/09/01 06:00
MHDA- 2021/11/03 06:00
CRDT- 2020/09/01 06:00
PHST- 2020/09/01 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2020/09/01 06:00 [entrez]
AID - 10.1007/s11523-020-00745-7 [pii]
AID - 10.1007/s11523-020-00745-7 [doi]
PST - ppublish
SO  - Target Oncol. 2020 Oct;15(5):589-598. doi: 10.1007/s11523-020-00745-7.